According to Sun Pharma, a number of divisions will be affected by the restructure: “As part of this process, the operations at Cranbury including inventory, products, manufacturing and lab equipment are being transferred to New Brunswick,” a spokesperson for the company told us.
“The restructuring is aimed at optimising our manufacturing operations and improving cost efficiencies in the increasingly competitive US market,” the spokesperson added.
The New Jersey Department of Labor and Workforce Development published a WARN notice this month, announcing that 96 jobs will be affected at Sun Pharma’s Cranbury facility.
“We are offering full support to the employees at Cranbury and helping them with internal reallocations and outplacement services,” the spokesperson told us.
Although cutting costs in the US, Sun Pharma continues to invest in its Indian manufacturing operations; last month, the firm installed a parenteral drug production line in Guwahati for the manufacture of sterile products.